Cite
HARVARD Citation
Mei, K. et al. (2021). Camrelizumab in combination with apatinib in second-line or above therapy for advanced primary liver cancer: cohort A report in a multicenter phase Ib/II trial. Journal for immunotherapy of cancer. 9 (3), p. . [Online].